VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer

NCT05489731 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Advanced Non-small Cell Lung Cancer

Interventions

DRUG: VIC-1911
DRUG: Osimertinib Mesylate Tablets

Sponsor

Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.